Neurotensin regulation of endogenous acetylcholine release from rat striatal slices is independent of dopaminergic tone.
The effects of neurotensin (NT) alone or in combination with the dopamine antagonist sulpiride were tested on the release of endogenous acetylcholine (ACh) from striatal slices. NT enhanced potassium (25 mM)-evoked ACh release from striatal slices in a dose-dependent manner. This effect was tetrodotoxin-insensitive, suggesting an action directly on cholinergic elements. The dopamine antagonist sulpiride (5 x 10(-5) M) significantly increased (63%) potassium-evoked ACh release from striatal slices; potassium-evoked ACh release was further increased (90%) in the presence of NT (10(-5) M) and sulpiride (5 x 10(-5) M). The second set of experiments tested the effects of 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra on NT-induced increases of potassium-evoked ACh release. These lesions did not alter the NT regulation of potassium-evoked ACh release from striatal slices, but did significantly increase spontaneous (33%) and potassium-evoked (40%) ACh release from striatal slices. Striatal choline acetyltransferase activity was not affected by 6-OHDA lesions. In addition, following 6-OHDA lesions, sulpiride was ineffective in altering ACh release from striatal slices. Furthermore, evoked ACh release in the presence of the combination of NT and sulpiride was not different from that in the presence of NT alone. These results suggest that in the rat striatum, NT regulates cholinergic interneuron activity by interacting with NT receptors associated with cholinergic elements. Moreover, the NT modulation of cholinergic activity is independent of either an interaction of NT with D2 dopamine receptors or the sustained release of dopamine.
Lapchak
P A
PA
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
Araujo
D M
DM
Quirion
R
R
Beaudet
A
A
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D006892:Hydroxydopamines / Q000494:pharmacology; D008297:Male; D009496:Neurotensin / Q000494:pharmacology*; D009627:Nomifensine / Q000494:pharmacology; D016627:Oxidopamine; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology; D013469:Sulpiride / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology
D018492:Dopamine Antagonists; D006892:Hydroxydopamines; D009627:Nomifensine; D009496:Neurotensin; D013779:Tetrodotoxin; D013469:Sulpiride; D016627:Oxidopamine; D000109:Acetylcholine; D011188:Potassium; D004298:Dopamine